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Abstract
The Human Proteome Organization (HUPO) Human Proteome Project (HPP) continues to make 
progress on its two overall goals: (1) completing the protein parts list, with an annual update of the 
HUPO draft human proteome, and (2) making proteomics an integrated complement to genomics 
and transcriptomics throughout biomedical and life sciences research. neXtProt version 
2017-01-23 has 17,008 confident protein identifications (Protein Existence [PE] level 1) that are 
compliant with the HPP Guidelines v2.1 (https://hupo.org/Guidelines), up from 13,664 in 2012-12 
and 16,518 in 2016-04. Remaining to be found by mass spectrometry and other methods are 2579 
“missing proteins” (PE2+3+4), down from 2949 in 2016. PeptideAtlas 2017-01 has 15,173 
canonical proteins, accounting for nearly all of the 15,290 PE1 proteins based on MS data. These 
resources have extensive data on PTMs, single amino acid variants, and splice isoforms. The 
Human Protein Atlas v16 has 10,492 highly-curated protein entries with tissue and subcellular 
spatial localization of proteins and transcript expression. Organ-specific popular protein lists have 
been generated for broad use in quantitative targeted proteomics using SRM-MS or DIA-SWATH-
MS studies of biology and disease.
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INTRODUCTION
The Human Proteome Organization (HUPO) (www.hupo.org) Human Proteome Project 
(HPP) is progressing toward two overall goals1: (1) completing stepwise the protein parts 
list, the draft human proteome, which is updated annually with an HPP Metrics 
publication2–5; and (2) integrating proteomics with genomics and transcriptomics for use 
throughout the biomedical/life sciences community. The protein parts list comprises at least 
one confidently identified protein product from each predicted protein-coding gene, along 
with post-translational modifications (PTMs), single amino acid variants (SAAVs), and 
splice isoforms of those proteins. The integration of proteomics with other ‘omics platforms 
has been enhanced through advances in assays, instrumentation, and knowledge bases for 
quantitative functional assessment of proteins and proteoforms in various biological systems. 
There are 50 HPP research teams worldwide organized by chromosome, mitochondria, 
biological processes, and disease categories, plus resource pillars for affinity-based protein 
capture, mass spectrometry, and knowledge bases. This Perspective is part of the 5th annual 
special issue of the Journal of Proteome Research2–5led by the Chromosome-centric HPP 
team (C-HPP).
Here we assess progress on identifying missing proteins (MP)—predicted proteins not 
previously reliably detected, having only neXtProt protein existence (PE) level 2, 3, or 4 
evidence. We discuss applications of the HPP Guidelines v2.1 for Interpretation of MS data6 
and emerging DIA-SWATH-MS data. Also, we highlight uncertainties in assessing claims of 
protein translation products from long non-coding RNAs.
The neXtProt and PeptideAtlas Metrics – Progress on the Human Proteome Parts List
PeptideAtlas7, 8 (www.peptideatlas.org) version 2017-01 and neXtProt version 2017-01-23 
(www.neXtProt.org), using HPP Guidelines for Interpretation of MS Data v2.16 (https://
hupo.org/Guidelines), provided the baseline for HPP investigators and others globally to 
identify MPs and to prepare HPP papers for this 2017 special issue. ProteomeXchange 
provides the platform for all proteomics investigators to contribute full raw datasets and 
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metadata to the community through PRIDE and SRMAtlas, as well as GPMDB, MassIVE, 
jPOST, and ProteomicsDB, leading to standardized reanalyses by PeptideAtlas and 
GPMDB. The scheme for the HPP Data Workflow was published last year5 (see 
Supplementary Figure 1). ProteomeXchange9, 10 had 3496 publicly released datasets, of 
which 1478 are from human samples, up from 900 a year ago 
(www.proteomecentral.proteomexchange.org) as of 2017-04-27. The 2016 HPP Metrics 
paper5 presented substantial detail about the features of PeptideAtlas, GPMDB, and 
neXtProt, including PTMs, proteoforms defined by N and C termini, sequence variants, and 
splice isoforms.
neXtProt published an update on its many features in January 2017, with emphasis on 
phenotypic annotations (especially hereditary cancers and channelopathies), phosphorylation 
and acetylation, sequence variants, and access tools11. Notable among these tools, and of 
particular usefulness for HPP projects in meeting the Guidelines v2.1 for protein 
identification at the PE1 level, is the new neXtProt “peptide uniqueness checker”12. This 
tool matches submitted peptides against all human protein sequences and their variants and 
isoforms; it was designed to determine which peptides map to human protein sequences 
uniquely versus mapping as well or better to previously validated proteins. For example, the 
peptide “TKMGLYYSYFK”, which was proposed to be unique to the PE2 protein 
DPY19L2P1 (Q6NXN4), maps to the PE1 proteins DPY19L2 (Q6NUT2) and DPY19L1 
(Q2PZI1) when SNPs are considered12.
Mass spectrometry datasets available via ProteomeXchange by October 2016 were included 
in PeptideAtlas 2017-01; a few details addressing nested peptides were added to the same 
datasets in version 2017-04-20. neXtProt uses the peptides evaluated by PeptideAtlas as the 
basis for mass spectrometry-based protein findings in its periodic updates. Table 1 shows the 
progression of highly confident protein identifications in neXtProt and in PeptideAtlas 
during the course of the HPP from 2012 to 2017.
During 2016 UniProtKB/SwissProt added 82 human protein entries, while 22 were 
deprecated and a few others were merged or de-merged. The changes in these numbers 
contributed to the net increase in total neXtProt entries from 20,055 to 20,159. Most of the 
remaining increment is due to inclusion of a set of 107 entries for immunoglobulin-coding 
genes, which were previously excluded by neXtProt but have since been extensively revised 
and accepted by UniProtKB/SwissProt curators. The number of confidently identified PE1 
proteins in neXtProt has grown from 13,664 in 2012 to 17,008 as of version 2017-01-23, and 
the canonical proteins in the Human PeptideAtlas have grown from 12,509 to 15,173, even 
after accommodating the more stringent guidelines between 2014 and 20165. From 2016 to 
2017, PE1 proteins and canonical proteins increased by 490 and 544, respectively (Table 1).
The criteria for the HPP MS Guidelines v2.1 were extensively discussed in HUPO Congress 
meetings, Bioinformatics Hub sessions, and Proteomics Standards Initiative workshops, and 
proposed publicly for comments from the whole community. When combining the results 
from analyzing hundreds of millions of PSMs, false positives become difficult to control 
with PSM confidence metrics alone. The false discovery rate among proteins with only a 
single peptide identification is well known to be much higher than those for which there are 
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multiple peptide identifications6. Therefore, in the pursuit of reliable evidence for difficult-
to-observe missing proteins, the community consensus now requires two uniquely mapping 
non-nested peptides with a minimum length of 9 amino acids13. The guidelines offer 
provisions for exceptions for proteins that could truly never be identified using these 
requirements; as an extreme example, ataxin-8 (NX_Q156A1) has the sequence methionine 
+ 79 glutamines (MQ79)! In many cases, researchers may meet the Guidelines v2.1 by using 
additional proteases14 or permitting missed cleavages or mis-cleavages.
Use of the more stringent v2.1 guidelines6 removed >400 proteins from PE1 status, as 
documented previously5; nearly all were attributed to requiring two uniquely-mapping non-
nested peptides, instead of one, which is necessary to reduce the false discovery rate (FDR) 
of protein identification. The difference between minimal length of 9 aa versus 8 aa peptides 
accounted for the exclusion of only 17 proteinsFN1. Expert manual examination of these 17 
(by EWD) indicated that about one-third are quite likely authentic detections, while two-
thirds were interpreted as equivocal in several different ways. As described previously6, 
shorter peptides suffer from fewer fragmentation peaks, which causes a higher rate of false 
positives, and are more likely to map to multiple genomic locations, particularly when 
sequence variants are considered. There could also be mapping to immunoglobulin variable 
regions. For these 17 exclusions, more experimental data are needed to achieve sufficient 
confidence that the protein truly has been detected.
Table 2 presents the numbers of predicted proteins in neXtProt in each of the PE levels. 
Clear experimental evidence for the existence of a protein is based on mass spectrometry in 
accordance with the HPP Guidelines v2.1 for 15,920 proteins and on the following non-MS 
methods for a further 1088 (see Figure 1): Edman sequencing (107), biochemical studies 
(131), PTMs (127), protein-protein interactions (372), antibody-based techniques (37), 3D 
structures (63), and disease mutations (251). Thereby, 87% of the human proteome has been 
identified to level PE1.
Figure 1 shows that the 2579 missing proteins (PE2+3+4) occur in two subsets: 453 with 
MS data that were excluded from PE1 due to the more stringent v2.1 Guidelines (down from 
485 in 2016) and 2126 others lacking sufficient evidence for PE1. The list of the accession 
numbers of the 453 protein entries not promoted to PE1 under PE1Rules.PA_NP_2015_12 
for both PeptideAtlas and neXtProt, but which would have been promoted to PE1 according 
to the older rules for neXtProt (PE1Rules.NP_2015_04) is available on the neXtProt ftp 
server at: ftp://ftp.nextprot.org/pub/current_release/custom/hpp/
HPP_entries_with_unconfirmed_MS_data.txt. The difference between the 15,173 canonical 
proteins in PeptideAtlas 2017-01 and the 15,920 from MS in Figure 1 is accounted for by 
proteins curated by neXtProt from MS studies of PTMs.
The total of 2579 is down by 370 from 2949 a year ago, mostly from extensive findings in 
sperm15 and testis16, studies that were guided by the tissue-based proteome from Human 
Protein Atlas17, the antibody profiling resource pillar of the HPP. For the 1939 PE2 proteins 
FN1neXtProt accession numbers for the 17 excluded proteins: NX_L0R8F8, NX_O15375, NX_P18825, NX_Q6NSI1, NX_Q7Z769, 
NX_Q8IUB2, NX_Q8IWZ4, NX_Q8N878, NX_Q8N957, NX_Q8WTQ1, NX_Q96A84, NX_Q96BR6, NX_Q96DU9, NX_Q9BQI4, 
NX_Q9BRU2, NX_Q9P109, NX_Q9UNT1.
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in Table 2, neXtProt, Human Protein Atlas, GeneCards (www.genecards.org), and GTEx 
(www.gtexportal.org) provide annotations about tissues with their highest transcript 
expression; such information represents a guide to choose specimens in which to search for 
evidence of expression of the protein. The same is true for the 563 PE3 protein entries 
identified by homology in other species. However, proper analysis of the median correlation 
between mRNA and protein levels from individual genes has shown quite low values (r = 
0.21), even ignoring the complexity of splice isoforms.18
Back in 2013, the HPP decided to exclude the PE5 category (572 entries) from the 
denominator, as those genome sequences are considered “dubious” or “uncertain” as 
candidates for protein-coding3 and about half are pseudogenes. If and when curated 
evidence supports moving PE5 entries higher, we will, of course, include such findings.
In 2016-17 the Human Protein Atlas released the Human Transcriptome19 and the Human 
Cell Atlas20, 21. The transcriptome map complements work from the Genome-based Tissue 
Expression Project GTEx (www.gtexportal.org) and Fantom consortium 
(fantom.gsc.riken.jp), plus several other repositories and maps. About 45% of the 18,864 
transcripts are expressed in all tissues and 13% in many tissues, while 13% (2359) were 
highly enriched in just one tissue, predominantly in testis/male reproductive tract and next in 
brain. Fresh frozen tissue and postmortem tissue gave very similar results. Tissue-specificity 
may be influenced by complex gene-regulatory patterns, including alternative splicing; 
isoform analysis of tissue-specificity and protein networks might be revealing22, 23. The 
Human Protein Cell Atlas was built in a crowd-sourcing spatial proteomics project with 
160,000 citizen-scientists examining immunohistochemical patterns for 12,000 proteins 
across 56 human cell lines, classified into 32 organelles and cellular structures 
(www.proteinatlas.org/cell; https://www.eveonline.com/discovery-proteins). A major quality 
control effort on antibodies has been launched by the International Working Group on 
Antibody Validation.24
The Search for Missing Proteins
To accelerate the completion of a high-quality draft of the human proteome, the C-HPP has 
mounted an initiative known as “The neXt-50 Challenge.” The aim is for each Chromosome 
team to plan how to identify up to 50 or more missing proteins from its respective 
chromosome (Supplementary Table 1) in time for the HUPO-2018 Congress. Noting that 
three chromosomes (13, 18, Y) and mitochondria had less than 50 total missing proteins and 
that many proteomics analyses are inherently chromosome-agnostic, teams were encouraged 
to share datasets for annotation and thereby contribute to the identification of additional 
missing proteins from other chromosomes. Three chromosomes (1, 11, 19) have >200 
missing proteins. Progress is to be updated on the C-HPP Wiki (http://c-
hpp.webhosting.rug.nl/tiki-index.php?page=Group%20composition).
Duek et al25 last year published a model analysis of the 134 and 93 missing proteins on 
chromosomes 2 and 14, respectively, a total of 227, and their strategy for identifying the 
likely most detectable missing proteins in spermatozoa. The authors put aside 29 predicted 
olfactory receptor proteins, 2 pseudogenes, 6 proteins refractory to tryptic digestion for MS, 
plus 27 newly validated proteins, 42 known to them to be in the neXtProt/SwissProt curation 
Omenn et al. Page 5
J Proteome Res. Author manuscript; available in PMC 2018 March 28.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
pipeline, and 22 with single proteotypic peptides (a total of 128). Then they identified 25 
chromosome 2 and 15 chromosome 14 predicted proteins with highest priority for successful 
analyses in spermatozoa. This year Carapito et al (this issue) report a total of 12 new PE1 
candidates from sperm for chromosomes 2 and 14. These results show how difficult it is to 
detect 50 missing proteins per chromosome, let alone all of the PE2-3-4 missing proteins in 
the entire proteome.
MissingProteinPedia26 (www.missingproteins.org) is a new on-line database from Australia 
with entries for missing proteins as of 2016. The database is populated with available 
information about 1482 of these proteins (as of 2017-07-24), including low-stringency MS 
hits, literature citations from a PubMed mining algorithm, and other information of variable 
reliability, which may provide clues that guide researchers to specific cells, tissues, or 
developmental stages for targeted investigation to find such missing proteins. Based on the 
MissingProteinPedia and neXtProt 2016-02, the 12 most numerous PE2–4 missing protein 
families are: G-protein coupled receptor 1 (including olfactory receptors), Krueppel C2H2-
type zinc-finger, beta defensin, PRAME, G-protein coupled receptor T2R, HPIP, humanin, 
LCE, MS4A, NBPF, peptidase C19/USP17 subfamily, and peptidase type B retroviral 
polymerase/HERV class II K(HML-2)26. A focus on analyses of protein families could be a 
productive strategy; as reflected in the PeptideAtlas categories of ambiguous protein 
matches, however, there are many challenges in distinguishing highly homologous proteins 
with shared or subsumed peptides8. Another strategy, tied to chromosome-specific analyses, 
is the detection and characterization of all members of amplicons, such as the 21 genes of 
the ERBB2 amplicon on chromosome 17q12-2127.
Status of Evidence for Translation Products from lncRNAs and smORFs
The Encyclopedia of DNA Elements (ENCODE) Project28, The Cancer Genome Atlas 
(TCGA), and a growing literature have documented gene regulatory functions and RNA/
protein interactions for a class of molecules known as long non-coding RNAs (lncRNAs)29 
(https://genome.ucsc.edu/ENCODE/). These lncRNAs are transcribed primarily from 
intergenic regions and from intronic regions within protein-coding genes. Iyer et al30 created 
a landscape of lncRNAs in the human transcriptome from 25 independent studies with 
91,000 expressed genome sequences, of which 59,000 coded for lncRNAs and 597 harbored 
ultraconserved elements. lncRNAs pose an important question for the HPP: Are any of these 
transcripts translated into polypeptides? If so, are the polypeptides present in biologically 
relevant amounts with distinct functions, or are they bystander products reflecting a dynamic 
system responding to cellular demands for a rapid protein translation capacity? Similar 
questions apply to small open-reading frames (smORFs), potentially yielding smORF-
encoded polypeptides (SEPs) or micropeptides31. How should the HPP evaluate and 
potentially include these novel protein candidates as bona fide components of the human 
proteome and the HPP metrics? Also, the HPP lacks policies for classifying peptides versus 
proteins and for recognizing bioactive cleavage products from known proteins; examples 
include endostatin, derived from collagen XVIII, and asprosin, a C-terminal 140 aa 
polypeptide hormone secreted from white adipose tissue, annotated under its parent protein, 
fibrillin 1 (FBN1, NX_P35555)32.
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Five prominent lncRNA researchers published a joint paper in Cell in 2013 concluding that 
ribosome profiling provides evidence that large noncoding RNAs do not encode proteins, 
even when they are shown to bind to 80S ribosomes33. Caviello34 similarly concluded that 
few lncRNAs generate protein products. In contrast, Slavoff et al35 presented evidence for 
90 SEPs in human K562 cell line samples, extending the 2007 report from Oyama et al36; 
synthetic peptides were used, but many of the spectral matches appear suspect. The 
developers of the LNCipedia resource37 performed extensive re-analysis of data sets 
deposited in the PRIDE repository38 for 21,488 human lncRNA transcripts; they searched 
for peptide matches, but reported more decoy hits than forward matches.39, 40 Meanwhile, 
Wang et al41 reported assays of the “translatome”, mRNAs captured in the initiation of 
translation on polyribosomes; they have presented evidence for lncRNAs identified in the 
translatome at two 2017 C-HPP workshops. The scarcity of credible protein products may be 
because mass spectrometry techniques are biased against them, they have low abundance 
due to low efficiency of synthesis or rapid degradation, or they are really not present, with 
the deduced peptides mapping better to known proteins. Verheggen et al42 showed that 
potential MS biases due to protein length, amino acid composition, abundance, instability, or 
mRNA expression level are minimal.
Analyses of large numbers of speculative sequences are fraught with perils of false positives 
overwhelming true detections of variants and novel coding elements43. To address this 
problem, the HPP MS Dataset Interpretation Guidelines v2.1 were designed as an 
embodiment of the mantra “extraordinary claims require extraordinary evidence” (https://
en.wikipedia.org/wiki/Sagan_standard); here claims of detecting proteins from lncRNAs are 
the “extraordinary claims.” Thus, for such “found proteins”, the Guidelines require two non-
nested, uniquely-mapping peptides of at least 9 residues in length with excellent high-
resolution spectral matches confirmed with synthetic peptide spectra, and with a process for 
ruling out alternative explanations for the confirmed peptide sequences, taking into account 
SAAVs and isobaric PTMs6. As yet, detection claims of SEPs and translated lncRNAs have 
not met the HPP guidelines. For some small products it may not be possible to obtain two 
non-nested uniquely-mapping peptides of at least 9 residues from protease digestion even 
when using alternative enzymes to trypsin14. Other corroborating evidence will be necessary 
in such cases, using specific antibodies, demonstrating biological function, or showing 
impacts on cellular processes from knockdowns. When evidence can be presented that meets 
the HPP Guidelines and neXtProt curation criteria, these sequences will enter the HPP 
knowledge base through PeptideAtlas and neXtProt. It will be interesting to see how this 
sub-field of proteogenomics progresses and whether lncRNAs contribute bona fide 
polypeptides with biological activity to the human proteome.
DIA-SWATH-MS Data
As discussed above, the HPP MS Dataset Interpretation Guidelines v2.1 provide specifics 
for validating claims of missing protein identifications or novel protein-coding elements via 
data-dependent analysis (DDA) and via SRM, both of which require using synthetic 
peptides44,45. Data-independent analysis (DIA) such as SWATH-MS (sequential window 
acquisition of all theoretical spectra) has emerged as an alternative workflow for protein 
identification and quantification46,47. Currently, the HPP Guidelines are silent on how to 
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apply them to DIA data sets. This was intentional as it seemed too early in the rapid 
advancement of DIA techniques to apply the guidelines. Now, it is time to begin a process to 
clarify the application and adaptation of the guidelines to DIA data.
We briefly describe here our suggested interpretation of the guidelines as they should apply 
to DIA. Guidelines 1–9 (see Supplementary Table 3) are directly applicable: the checklist, 
data deposition in a ProteomeXchange repository with the required proteome reference, and 
issues related to false discovery rates, which, due to the high degree of multiplexing with 
SWATH-MS, may be even more important and challenging than for other workflows. 
Guidelines 10–15 apply only to claims of detection of proteins or other translation products 
that are not PE1. If a DIA data set is analyzed similar to a DDA data set, using tools such as 
DIA-Umpire48 or DISCO, then guidelines 10–12 apply. If a DIA dataset is analyzed similar 
to an SRM dataset, using tools such as Skyline49, OpenSWATH46, Spectronaut, or 
PeakView, then guideline 13 applies instead. In both of these cases the peptide signatures 
must show concordance with the corresponding synthetic peptide signatures. Guidelines 14–
15 are independent of data type and apply to any analysis workflow, including DIA. As with 
the original Guidelines, we will promote a community discussion and refinement of these 
ideas, with the aim of releasing an updated version at year-end.
CONCLUDING REMARKS
The HUPO Human Proteome Project draft human proteome in neXtProt 2017-01-23 reached 
17,008 high confidence neXtProt PE1 protein identifications, representing 87% of the 
neXtProt predicted PE1–4 proteins, with 15,920 from MS/MS and 1088 from other kinds of 
protein studies. Continuing progress will be reported regularly in the C-HPP Wiki, HUPO 
website, and in this and future HPP Special Issues of the Journal of Proteome Research. 
[The neXtProt 2017-04-20 update at www.nextprot.org has 17,045 PE1 proteins with 2563 
PE2,3,4 missing proteins; clearly, the metrics are a moving target during each annual cycle.]
Meanwhile, the scheme from the Biology and Disease-driven HPP to utilize organ-specific 
lists of popular proteins in combination with quantitative multiplexed targeted proteomics 
assays50 is a stimulus for broader use of proteomics in many areas of life sciences research. 
Attention to the biological diversity enhanced by alternative proteoforms will advance 
understanding of strategies that have evolved to maintain homeostasis in the face of 
challenges from infection, disease, injury, aging, nutritional and environmental stress, and 
hormonal variations.
Given the importance of targeted proteomics with SRM or PRM-MS methods or DIA-
SWATH-MS, the HPP is addressing the application of the HPP Guidelines for interpretation 
of DIA-SWATH MS data. Finally, we are considering the potential expansion of the 
proteome to include any credible translation products from long non-coding RNAs, small 
open reading frame sequences, and bioactive cleavage of known proteins.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Distribution of neXtProt predicted proteins by protein existence (PE) level and the nature of 
the evidence data as of version 2017-01. Supplementary Table 1 presents the status of 
neXtProt results by PE level for each chromosome as of version 2017-01. Supplementary 
Table 2 the classification of proteins in PeptideAtlas by chromosome (version 2017-04).
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Table 1
Metrics of the Progress in the HPP Draft Human Proteome from 2012 to 2017. Numbers shown are of highly 
confident protein identifications in neXtProt and Peptide Atlas in each of the annual metrics reports in the 
special issues of the Journal of Proteome Research2–5.
Chr.
neXtProt Protein
Entries
neXtProt
PE1
Proteins
Human
PeptideAtlas
Canonical
Dec 2012 all 20,059 13,664 12,509
Sep 2013 all 20,123 15,646 13,377
Oct 2014 all 20,055 16,491 14,928
Apr 2016 all 20,055 16,518a 14,629
Jan 2017 all 20,159a 17,008 15,173
a
PE 1–4 = 19,587
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